Heron Therapeutics Reaffirms Availability And Supply Of CINVANTI, SUSTOL and APONVIE As Alternatives During Potential Intravenous Fluids Shortage
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics has confirmed the availability and supply of its products CINVANTI, SUSTOL, and APONVIE as alternatives during a potential intravenous fluids shortage.
October 10, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Heron Therapeutics has reassured the market about the availability of its products CINVANTI, SUSTOL, and APONVIE, which could serve as alternatives during a potential intravenous fluids shortage.
The confirmation of product availability by Heron Therapeutics during a potential shortage of intravenous fluids is likely to positively impact the company's stock. This reassurance can lead to increased demand for their products, potentially boosting revenues and investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90